Honored to speak at Harvard’s Radcliffe Institute workshop on #LongCOVID. I am energized by our 2 days of brainstorming about the road ahead. The challenges are real, but I’m leaving hopeful. Millions living with Long Covid are counting on our progress—we must keep keep pushing forward!!!

New Long Covid policy paper from Norway outlines knowledge gaps and lessons learnt for developing preparedness for future pandemics.

Section 5 (pictured below) outlines their recommendations. Led by Sara Illman, PhD and colleagues.

www.nordforsk.org/2025/knowled...

The beneficial effects on many conditions (e.g. Alzheimer’s) may implicate GLP1 in their mechanisms – and open new therapeutic avenues (e.g. GLP1 could play a role in mechanism of Alzheimer’s and may be effective treatments)

www.nature.com/articles/s41...

GLP1 increased risks of gastrointestinal disorders, hypotension, syncope, arthritic disorders,
nephrolithiasis, interstitial nephritis and drug-induced pancreatitis.

GLP1 reduced risks of substance use and psychotic disorders,
seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders, cardiometabolic disorders, infectious
illnesses and several respiratory conditions.

The results show that GLP1 have a wide-ranging beneficial profile but are not without risks.

GLP1 meds were associated with reduced risk of 42 (24%) outcomes and increased risk of 19 outcomes (11%).

www.nature.com/articles/s41...

We included several controls - people on sulfonylureas, DPP4 inhibitors, SGLT2 inhibitors and people on usual care who did not start GLP1
We followed study participants for 3.7 years
www.nature.com/articles/s41...

So, we decided to do the comprehensive study!

We did a discovery analysis which comprehensively examined 175 possible health outcomes (leaving no stone unturned) in 215,970 people on GLP1 and more than 2 million individuals not on GLP1.

www.nature.com/articles/s41...